A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer

Vandana G. Abramson,Mafalda Oliveira,Andrés Cervantes,Hans Wildiers,Manish R. Patel,Todd Michael Bauer,Philippe L. Bedard,Carlos Becerra,Stephen Lane Richey,Michael C. Wei,Eric Reyner,John Bond,Na Cui,Timothy R. Wilson,Heather M. Moore,Cristina Saura,Ian E. Krop

A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer

2019

Vandana G. Abramson
Mafalda Oliveira
Andrés Cervantes
Hans Wildiers
Manish R. Patel
Todd Michael Bauer
Philippe L. Bedard
Carlos Becerra
Stephen Lane Richey
Michael C. Wei
Eric Reyner
John Bond
Na Cui
Timothy R. Wilson
Heather M. Moore
Cristina Saura
Ian E. Krop

Purpose This open-label, phase Ib, dose-escalation, and dose-expansion study (NCT01862081) evaluated taselisib with a taxane in locally advanced or metastatic breast cancer (BC) and/or non-small cell lung cancer (NSCLC).

Keywords:

HER2 negative
Cancer research
Cell
Taxane
Lung cancer
Metastatic breast cancer
Paclitaxel
Medicine
Docetaxel
Capsule
Internal medicine
Adverse effect
locally advanced
Oncology
Pharmacokinetics

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations